002262: Jiangsu Nhwa Pharmaceutical Co., LTD - Summary | Jitta

Jiangsu Nhwa Pharmaceutical Co., LTD

CHN:002262

Price
CN¥22.42
Loss Chance
44.6%
6.11JITTA SCORE
106.43%Over Jitta Line
Jitta Ranking
120 / 487
1,160 / 5,259
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (43)
Recent Business Performance (40)
Financial Strength (88)
Return to Shareholders (71)
Competitive Advantage (63)
Jitta Signs
Revenue and EarningConsistent
Debt LevelLow Long Term Debt
Dividend PayoutIncreasing Every Year
SG&A to SalesDecreasing
Operating MarginDeclined
Recent Business PerformanceEarning decline 7.39% in the last year
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
6.11
106.43%
4.42
> 1,000%
4.24
> 1,000%
Pharmaceuticals
6.36
2.64%
5.47
25.22%
7.76
43.10%
COMPANY DESCRIPTION
Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin fumarate injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, olanzapine tablets, midazolam hydrochloride oral solution, clonazepam injection, lacosamide injection, micuronium injection, pregabalin capsules, vortioxetine hydrobromide tablets, tapentadone hydrochloride tablets, and oxycodone hydrochloride extended-release tablets. The company was founded in 1978 and is headquartered in Xuzhou, China.